Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Pipeline Review, H1 2018

  • ID: 4482717
  • Drug Pipelines
  • 74 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Atossa Genetics Inc
  • Eagle Pharmaceuticals Inc
  • Eli Lilly and Co
  • Endece LLC
  • EndoCeutics Inc
  • MORE
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Pipeline Review, H1 2018

Summary:

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

The latest report Estrogen Receptor Beta - Pipeline Review, H1 2018, outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 4, 1, 5 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Women's Health, Male Health, Metabolic Disorders, Dermatology and Immunology which include indications Breast Cancer, Multiple Sclerosis, Endometriosis, Hormone Sensitive Breast Cancer, Neuropathic Pain, Prostate Cancer, Vasomotor Symptoms of Menopause (Hot Flashes), Alzheimer's Disease, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Cognitive Impairment Associated With Schizophrenia (CIAS), Colon Cancer, Demyelinating Diseases, Depression, Ductal Carcinoma In Situ, Encephalopathy, Inflammation, Male Hypogonadism, Malignant Pleural Mesothelioma, Neurology, Obesity, Osteoporosis, Vaginal Atrophy (Atrophic Vaginitis) and Vulvar Atrophy.

Furthermore, this report also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)
  • The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Atossa Genetics Inc
  • Eagle Pharmaceuticals Inc
  • Eli Lilly and Co
  • Endece LLC
  • EndoCeutics Inc
  • MORE
Introduction

Report Coverage

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Overview

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Companies Involved in Therapeutics Development

Acadia Pharmaceuticals Inc

AstraZeneca Plc

Atossa Genetics Inc

Eagle Pharmaceuticals Inc

Eli Lilly and Co

Endece LLC

EndoCeutics Inc

Karo Pharma AB

Kissei Pharmaceutical Co Ltd

MEI Pharma Inc

Mithra Pharmaceuticals SA

Oasmia Pharmaceutical AB

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Drug Profiles

AC-186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene hydrochloride + prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUS-131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize ER-Beta for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erteberel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estetrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KB-3944 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KB-9520 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Libidua - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Loseasonique - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDC-1308 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDC-1352 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize ESR2 for Obesity and Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-16234 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Dormant Products

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Discontinued Products

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Product Development Milestones

Featured News & Press Releases

Jan 25, 2018: Mithra Announces Last Subject Completes Donesta Phase II Study

Dec 11, 2017: AstraZeneca’s Faslodex Rejects For Use Within NHS Scotland

Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant

Nov 30, 2017: Mithra Provides Update On DONESTA Study

Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib

Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib

Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib

Oct 13, 2017: Mithra Announces Completion of Recruitment in Donesta Phase II Study

Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective

Aug 28, 2017: Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer

Jul 26, 2017: Faslodex receives EU approval as first-line therapy for advanced breast cancer

Jul 25, 2017: Atossa Genetics Provides Update on Fulvestrant Microcatheter Phase 2 Study

Jul 06, 2017: Mithra Strengthens E4 Patent Position in Australian Market

Jun 23, 2017: Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer

Jun 21, 2017: Mithra Completes Recruitment For Additional Estelle Safety Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Acadia Pharmaceuticals Inc, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Atossa Genetics Inc, H1 2018

Pipeline by Eagle Pharmaceuticals Inc, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Endece LLC, H1 2018

Pipeline by EndoCeutics Inc, H1 2018

Pipeline by Karo Pharma AB, H1 2018

Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018

Pipeline by MEI Pharma Inc, H1 2018

Pipeline by Mithra Pharmaceuticals SA, H1 2018

Pipeline by Oasmia Pharmaceutical AB, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acadia Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atossa Genetics Inc
  • Eagle Pharmaceuticals Inc
  • Eli Lilly and Co
  • Endece LLC
  • EndoCeutics Inc
  • Karo Pharma AB
  • Kissei Pharmaceutical Co Ltd
  • MEI Pharma Inc
  • Mithra Pharmaceuticals SA
  • Oasmia Pharmaceutical AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll